Second Sight Announces Significant Results From The Argus? II Retinal Prosthesis Trial At The ARVO 2011 Annual Meeting

Exciting results from the Argus? II Retinal Prosthesis System ('Argus II') clinical trial were presented today at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) 2011 Annual Meeting. The clinical trial included 30 subjects implanted in 10 centers worldwide, and has run for nearly 4 years. The results that were presented from the trial showed that the Argus II System provided significant improvements in vision for the blind subjects who are suffering from profound Retinitis Pigmentosa (RP). Two paper presentations outlined the safety, reliability and performance of the system. In February 2011, Argus II became the first such treatment for the blind to obtain the CE Mark and make the leap from research to the marketplace in Europe. An application for FDA approval in the US is being submitted in 2011.